Open AccessVirological responses during treatment for recent hepatitis C virus
Author(s) -
Jason Grebely,
Margaret Hellard,
Tanya Applegate,
Kathy Petoumenos,
Barbara Yeung,
Jordan J. Feld,
William D. Rawlinson,
Andrew R. Lloyd,
Jacob George,
John Kaldor,
Gregory J. Dore,
Gail V. Matthews
Publication year - 2012
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e3283553719
Subject(s) - medicine , ribavirin , hepatitis c virus , hepatitis c , pegylated interferon , immunology , hepacivirus , gastroenterology , viral load , alpha interferon , virus , virology , interferon
The role of ribavirin (RBV) in the treatment of recent hepatitis C virus (HCV) (acute/early chronic) is unclear, particularly in HIV-infected individuals. This study evaluated early virological decline during recent HCV therapy in HIV-uninfected individuals receiving pegylated interferon (PEG-IFN) monotherapy and HIV-infected individuals receiving PEG-IFN/RBV.